BioSpace13d
FDA Still Undecided About Shortage Status of Lilly’s Tirzepatide
Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
STAT1d
Compounding pharmacies rebut Novo’s FDA petition
The Alliance for Pharmacy Compounding rebutted Novo's FDA petition to bar compounding pharmacies from copying its weight loss ...
BioSpace9d
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
health.wusf.usf.edu15d
Drugmakers and pharmacists battle over who gets to make obesity drugs
Ozempic and similar drugs for Type 2 diabetes and weight loss are in such ... Novo Nordisk and Eli Lilly are moving ...
Yahoo17d
5 new weight-loss drugs to watch in the fight for the next Ozempic
GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...